CytoMed Therapeutics (GDTC) is trading up at $1.01 (+9.78%), as of the latest quote. It operates in the Health Care sector.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | — | — | — | SGD 69.5K | SGD 324.4K |
| Growth (year over year) | — | — | — | — | — | +366.7% |
| Net income | −SGD 1.94M | −SGD 2.05M | −SGD 3.13M | −SGD 4.13M | −SGD 2.52M | −SGD 3.98M |
| Net margin | — | — | — | — | −3621.1% | −1227.1% |
| EPS (diluted) | −SGD 0.33 | −SGD 0.30 | −SGD 0.40 | −SGD 0.39 | −SGD 0.22 | −SGD 0.34 |
| Balance sheet | ||||||
| Cash and equivalents | SGD 885.3K | SGD 2.51M | SGD 1.58M | SGD 6.22M | SGD 4.70M | SGD 2.10M |
| Total assets | — | SGD 6.08M | SGD 5.23M | SGD 12.4M | SGD 10.1M | SGD 7.98M |
| Total liabilities | — | SGD 3.49M | SGD 4.64M | SGD 1.12M | SGD 1.02M | SGD 1.13M |
| Shareholders' equity | SGD 475.8K | SGD 2.59M | SGD 587.0K | SGD 11.2M | SGD 8.97M | SGD 6.54M |
| Cash flow | ||||||
| Operating cash flow | −SGD 849.4K | −SGD 1.71M | −SGD 1.40M | −SGD 3.53M | −SGD 2.71M | −SGD 3.70M |
| Capital expenditure | SGD 244.7K | SGD 582.4K | SGD 473.8K | SGD 58.3K | SGD 1.40M | SGD 637.9K |
| Free cash flow | −SGD 1.09M | −SGD 2.30M | −SGD 1.87M | −SGD 3.59M | −SGD 4.11M | −SGD 4.34M |
From CytoMed Therapeutics's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Amounts are in Singapore Dollar (SGD), as reported, not converted to dollars. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning CytoMed Therapeutics in our feed yet.